Details

Autor(en) / Beteiligte

• Chen, Liudan
• Tao, Yangu
• Li, Jianjun
• Kang, Mengru

Titel

Pioglitazone use is associated with reduced risk of Parkinson’s disease in patients with diabetes: A systematic review and meta-analysis

Ist Teil von

• Journal of clinical neuroscience, 2022-12, Vol.106, p.154-158

Ort / Verlag

Elsevier Ltd

Erscheinungsjahr

2022

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• •There was a significant reduction in the risk of parkinson’s disease in pioglitazone users.•Pioglitazone could reduce the risk of parkinson’s disease in diabetes patients.•438 dose-duration-days of pioglitazone could be beneficial for parkinson’s disease in diabetes patients. This meta-analysis aimed to evaluate the effect of pioglitazone on Parkinson’s disease (PD) in diabetes patients. A study search was carried out in PubMed, Embase, and Web of Science databases from inception to July 22, 2021. The Newcastle-Ottawa scale was used to evaluate the quality of the eligible studies. The risk ratio (RR) and 95% confidence intervals (CI) were used as effect size indicators in this meta-analysis to evaluate the risk association between pioglitazone and PD. The Cochran’s Q and I2 tests were used to assess statistical heterogeneity. A dose–response meta-analysis was conducted using the least squares trend estimation method. Three studies were eligible for this meta-analysis. Compared with diabetes patients who did not use pioglitazone, there was a significant reduction in the risk of PD (RR of 0.87 [95 % CI 0.62–0.99, P = 0.039]) in pioglitazone users. No significant difference in PD risk was noted in diabetes patients taking 438 dose-duration-days (DDDs) of pioglitazone or lower compared with those who did not. When the DDD of pioglitazone was 438, the RR was 0.85 (95 % CI [0.72–1.00], P = 0.05). When the DDD of pioglitazone was > 438, the risk of PD in patients with diabetes was significantly decreased (P < 0.05) and showed an approximate linear correlation trend. Pioglitazone administration in PD in diabetes patients is significantly associated with a decrease in the risk of PD.